These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 20148735)

  • 21. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome.
    Frere C; Cuisset T; Quilici J; Camoin L; Carvajal J; Morange PE; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
    Thromb Haemost; 2007 Oct; 98(4):838-43. PubMed ID: 17938809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
    Gilard M; Arnaud B; Cornily JC; Le Gal G; Lacut K; Le Calvez G; Mansourati J; Mottier D; Abgrall JF; Boschat J
    J Am Coll Cardiol; 2008 Jan; 51(3):256-60. PubMed ID: 18206732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome.
    Cuisset T; Hamilos M; Delrue M; Frère C; Verhamme K; Bartunek J; Saut N; Bonnet JL; Eijgelsheim M; Wijns W; Alessi MC; Barbato E
    Thromb Haemost; 2010 Apr; 103(4):774-9. PubMed ID: 20135061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease.
    Lordkipanidzé M; Diodati JG; Schampaert E; Palisaitis DA; Pharand C
    Am J Cardiol; 2009 Nov; 104(9):1189-93. PubMed ID: 19840560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay.
    Abtan J; Silvain J; Kerneis M; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Collet JP; Montalescot G
    Thromb Haemost; 2013 Nov; 110(5):1055-64. PubMed ID: 23925438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
    Freynhofer MK; Brozovic I; Bruno V; Farhan S; Vogel B; Jakl G; Willheim M; Hübl W; Wojta J; Huber K
    Thromb Haemost; 2011 Aug; 106(2):230-9. PubMed ID: 21614416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery.
    Alström U; Granath F; Oldgren J; Ståhle E; Tydén H; Siegbahn A
    Thromb Res; 2009 Nov; 124(5):572-7. PubMed ID: 19631364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction.
    Osmancik P; Jirmar R; Hulikova K; Peroutka Z; Pompachova A; Motovska Z; Widimsky P
    Catheter Cardiovasc Interv; 2010 Feb; 75(2):158-66. PubMed ID: 19902490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography?
    Cotton JM; Worrall AM; Hobson AR; Smallwood A; Amoah V; Dunmore S; Nevill AM; Raghuraman RP; Vickers J; Curzen N
    Cardiovasc Ther; 2010 Jun; 28(3):139-46. PubMed ID: 20406238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients.
    Gurbel PA; Bliden KP; Etherington A; Tantry US
    Thromb Res; 2007; 121(1):107-15. PubMed ID: 17400283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
    Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of platelet P2Y(12) ADP receptor-mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP-phosphorylation in Japanese patients undergoing coronary stenting.
    Fu Q; Yokoyama N; Takada K; Ishikawa S; Isshiki T
    Int Heart J; 2010; 51(5):303-7. PubMed ID: 20966600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials.
    Lemesle G; Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM
    Platelets; 2014; 25(7):499-505. PubMed ID: 24176022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel.
    Malinin A; Pokov A; Swaim L; Kotob M; Serebruany V
    Methods Find Exp Clin Pharmacol; 2006 Jun; 28(5):315-22. PubMed ID: 16845449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.
    Siller-Matula JM; Lang I; Christ G; Jilma B
    J Am Coll Cardiol; 2008 Nov; 52(19):1557-63. PubMed ID: 19007592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis.
    Morel O; Faure A; Ohlmann P; Jesel L; Desprez D; Grunebaum L; Bareiss P
    Thromb Haemost; 2007 Oct; 98(4):896-9. PubMed ID: 17938817
    [No Abstract]   [Full Text] [Related]  

  • 37. Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity.
    Aradi D; Rideg O; Vorobcsuk A; Magyarlaki T; Magyari B; Kónyi A; Pintér T; Horváth IG; Komócsi A
    Eur J Clin Invest; 2012 Apr; 42(4):384-92. PubMed ID: 21902692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
    Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
    Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.
    Varenhorst C; James S; Erlinge D; Braun OO; Brandt JT; Winters KJ; Jakubowski JA; Olofsson S; Wallentin L; Siegbahn A
    Am Heart J; 2009 Mar; 157(3):562.e1-9. PubMed ID: 19249429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
    Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
    Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.